Fundraising Foxage1 — 2025 Investments
3 investments dated 2025 · listed companies and verified rows first · show all
General Proximity develops proximity-based technologies for drug discovery and development.
AI & Machine LearningBiotechDeep TechHealthtechSan Francisco, US
Armand Cognetta(Founder)inMatthias PauthnerCorentine Laurin(Principal Scientist, Medicinal Chemistry)Veronica Fulton(Chief of Staff)Benji Dote(EA)Reen Ramos(EA)
Co-investorsY CombinatorFelicis VenturesFreemind InvestmentsLifespan Vision VenturesLong GameMana Ventures+4 more
NewLimit develops epigenetic reprogramming medicines to extend healthspan and treat age-related diseases at the intersection of computer science and biotechnology.
AI & Machine LearningBiotechLongevitySouth San Francisco, US
Brian Armstrong(Founder)inBlake Byers(Founder)inJacob Kimmel(Founder)inMichael Polansky(Executive Officer)
BoardZavain Dar(Director)in
Co-investorsS32Valor Equity Partners8VCAbstract VenturesBeyond CapitalCapital B Private Holdings+15 more
Skeletalis is developing OASIS, a targeted small-molecule platform for musculoskeletal and bone health that concentrates therapy at sites of active bone loss while preserving the body's natural bone remodeling.
BiotechDeep TechHealthtech
Co-investorsPillar VCKdT Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.